Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
08 nov. 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
07 nov. 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
03 nov. 2022 09h05 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced early clinical findings from its ongoing proof-of-concept...
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
10 oct. 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Clinical and pre-clinical data from across the company’s portfolio will be featured in four oral and six poster presentations Co-founder and Chief Executive Officer Bobby Gaspar to give invited talk...
Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
29 août 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio...
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
04 août 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Additional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven...
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
12 mai 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European...
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
10 mai 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at...
Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
05 mai 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
02 mai 2022 07h00 HE
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche...